|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,500,000 |
Market
Cap: |
2.03(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.65 - $65 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
32,136 |
396,652 |
637,244 |
1,063,187 |
Total Sell Value |
$1,498,005 |
$22,240,305 |
$34,650,077 |
$50,026,056 |
Total People Sold |
3 |
6 |
9 |
11 |
Total Sell Transactions |
5 |
14 |
31 |
71 |
End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shandell Jason B. |
President and General Counsel |
|
2020-02-06 |
4 |
AS |
$19.83 |
$434,951 |
D/D |
(21,933) |
138,898 |
|
4% |
|
Shandell Jason B. |
President and General Counsel |
|
2020-02-06 |
4 |
OE |
$14.40 |
$315,835 |
D/D |
21,933 |
160,831 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2020-02-05 |
4 |
AS |
$19.57 |
$305,554 |
D/D |
(15,615) |
138,898 |
|
5% |
|
Shandell Jason B. |
President and General Counsel |
|
2020-02-05 |
4 |
OE |
$14.40 |
$224,856 |
D/D |
15,615 |
154,513 |
|
- |
|
Petersen Floyd F. |
Director |
|
2020-02-03 |
4 |
AS |
$19.12 |
$9,558 |
D/D |
(500) |
73,142 |
|
4% |
|
Shandell Jason B. |
President and General Counsel |
|
2020-01-08 |
4 |
AS |
$18.44 |
$460,978 |
D/D |
(25,000) |
138,898 |
|
-1% |
|
Shandell Jason B. |
President and General Counsel |
|
2020-01-08 |
4 |
OE |
$10.93 |
$273,250 |
D/D |
25,000 |
163,898 |
|
- |
|
Petersen Floyd F. |
Director |
|
2020-01-02 |
4 |
AS |
$19.14 |
$19,142 |
D/D |
(1,000) |
73,642 |
|
-0% |
|
Shandell Jason B. |
President and General Counsel |
|
2019-12-18 |
4 |
AS |
$19.13 |
$156,958 |
D/D |
(8,205) |
138,898 |
|
- |
|
Petersen Floyd F. |
Director |
|
2019-12-02 |
4 |
AS |
$19.25 |
$9,623 |
D/D |
(500) |
74,642 |
|
- |
|
Petersen Floyd F. |
Director |
|
2019-11-01 |
4 |
AS |
$19.48 |
$9,738 |
D/D |
(500) |
75,142 |
|
- |
|
Petersen Floyd F. |
Director |
|
2019-10-01 |
4 |
AS |
$19.92 |
$9,959 |
D/D |
(500) |
75,642 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2019-09-18 |
4 |
AS |
$21.32 |
$156,509 |
D/D |
(7,340) |
147,103 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2019-09-16 |
4 |
AS |
$21.76 |
$213,256 |
D/D |
(9,800) |
82,453 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2019-09-16 |
4 |
OE |
$11.33 |
$111,034 |
D/D |
9,800 |
92,253 |
|
- |
|
Petersen Floyd F. |
Director |
|
2019-09-16 |
4 |
AS |
$21.75 |
$10,877 |
D/D |
(500) |
76,142 |
|
- |
|
Liawatidewi Yakob |
SVP Corp Admin Center |
|
2019-09-13 |
4 |
S |
$21.45 |
$64,340 |
D/D |
(3,000) |
33,670 |
|
- |
|
Applied Physics & Chemistry Laboratories, Inc. |
COO,Chief Scientist & Chairman |
|
2019-09-11 |
4 |
S |
$20.82 |
$6,246,000 |
I/I |
(300,000) |
7,027,679 |
|
- |
|
Liawatidewi Yakob |
SVP Corp Admin Center |
|
2019-09-06 |
4 |
S |
$21.90 |
$52,455 |
I/I |
(2,395) |
2,459 |
|
- |
|
Liawatidewi Yakob |
SVP Corp Admin Center |
|
2019-09-05 |
4 |
S |
$21.24 |
$32,184 |
I/I |
(1,515) |
4,854 |
|
- |
|
Prins Richard K |
Director |
|
2019-08-26 |
4 |
S |
$22.60 |
$81,767 |
D/D |
(3,618) |
39,309 |
|
- |
|
Prins Richard K |
Director |
|
2019-08-26 |
4 |
OE |
$15.11 |
$54,668 |
D/D |
3,618 |
42,927 |
|
- |
|
Prins Richard K |
Director |
|
2019-08-23 |
4 |
S |
$22.58 |
$87,654 |
D/D |
(3,882) |
39,309 |
|
- |
|
Prins Richard K |
Director |
|
2019-08-23 |
4 |
OE |
$15.11 |
$58,657 |
D/D |
3,882 |
43,191 |
|
- |
|
Peters William J |
CFO, SVP & Treasurer |
|
2019-08-15 |
4 |
S |
$21.00 |
$103,782 |
D/D |
(4,942) |
82,453 |
|
- |
|
954 Records found
|
|
Page 17 of 39 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|